47.8 F
Clarksville
Thursday, March 28, 2024
HomeNewsRobot therapy can improve arm, shoulder mobility after stroke

Robot therapy can improve arm, shoulder mobility after stroke

American Heart AssociationLos Angeles, CA – Therapy in which robots manipulate paralyzed arms, combined with standard rehabilitation, can improve arm and shoulder mobility in patients after stroke, according to research presented at the American Stroke Association’s International Stroke Conference 2011.

Patients on robotic therapy showed marked improvement in two measures of upper extremity function: the Fugl-Meyer flexor synergy score, a 0 to 12 scale with higher numbers reflecting recovery of voluntary arm movement; and the Fugl-Meyer shoulder/elbow/forearm score, a 0 to 36 scale with higher numbers reflecting recovery of motor function in the shoulder, elbow and forearm.

[youtube]http://www.youtube.com/watch?v=7tDGTQ47w_4[/youtube]

“Combining robotic exercise with regular rehabilitation may be the key to successful intervention,” said Kayoko Takahashi, Sc.D., O.T.R., lead author of the study and clinician and research associate in the Department of Occupational Therapy in Kitasato University East Hospital in Kanagawa, Japan. Robots could allow therapists to focus on helping patients master daily activities while maintaining repetitive training, Takahashi said.

The new study involved 60 stroke survivors with hemiplegia (paralysis on one side of the body) treated at six rehabilitation centers in Japan. The patients, average age 65, had suffered a stroke in the previous four to eight weeks. All received standard rehabilitation therapy from an occupational therapist.

Half the group received robotic therapy every day for six weeks, in sessions lasting 40 minutes. The other half spent the same amount of time working through a standard self-training program for hemiplegic patients, performing stretches and passive-to-active exercises of their affected arm.

With a recent trend in helping patients function with one arm, “many post-stroke patients have given up hope of recovery of their affected arms.” Takahashi said. “Participating in such robotic exercise is therefore expected to give patients insights about their future ability and a more positive image regarding their affected arm, increasing their self-efficacy and motivation toward rehabilitation.”

The group assigned to robotic therapy used a Reo Therapy System by Motorika Ltd. in Israel. For the therapy, the patient’s forearm, either resting on or strapped to a platform, is moved in multiple directions based on pre-programmed exercise movements.

Researchers selected five such pre-programmed movements. For instance, in one of the movements, “forward reach,” the robot helps patients extend their arms forward as if reaching for something in front of them.

Therapists also selected from five levels of robotic assistance according to what was most appropriate for the patient, from movement entirely guided by the robot and passive on the patient’s part, to movement actively performed by the patient.

The successful test of robots adds a new wrinkle to stroke rehabilitation strategies, Takahashi said. While repetitive movement is an essential therapy, physical and occupational therapists aren’t always available to provide care, and self-training, if not done correctly, can result in pain and disability.

“Robots, on the other hand, can carry out the repetitive movement exercise with exactly the right movement pattern to prevent misuse,” Takahashi said.

Based on initial mobility scores, patients with severe hemiplegia were more likely to benefit from the robotic therapy.
The finding is consistent with the notion that higher-functioning patients already can correctly carry out self-training programs, while patients with lower function — only reflex and minor voluntary movement — are more likely to benefit from the support and aid of robots, Takahashi said.

“Further research using larger groups of patients is necessary to investigate the efficacy of such robotic exercise in more detail,” Takahashi said.

Co-authors are: Kazuhisa Domen, M.D., D.M.Sc.; Kenji Hachisuka, M.D., D.M.Sc.; Tomosaburo Sakamoto, M.D., Ph.D.; Masahiko Toshima, M.D.; Yohei Otaka, M.D.; Makiko Seto, M.D., Ph.D.; Katsumi Irie, M.D., Ph.D.; Bin Haga, M.D., Ph.D; and Tetsuhiko Kimura, M.D., Ph.D. Author disclosures are on the abstract.

The study was in funded in part by Teijin Pharma Limited.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

RELATED ARTICLES

Latest Articles